Question · Q4 2025
Seth Burgie asked about the impact of the Life Science IPO and M&A environment on Kilroy Oyster Point Phase Two (KOP2), specifically regarding changes in tour activity and the leasing pipeline. He also inquired about the remaining unannounced $175 million in dispositions, asking if they are targeted in specific markets and about the depth and evolution of the buyer pool.
Answer
Angela Aman, CEO, and Rob Paratte, EVP and Chief Leasing Officer, confirmed KOP2's pipeline has refilled despite recent executions, with consistent tour activity and strong momentum for remaining vacancy. Eliott Trencher, EVP of CIO, stated the buyer pool has improved with more institutional capital, allowing for larger transaction sizes, particularly in San Francisco. Angela added that they will evaluate the entire portfolio for efficient pricing, noting renewed institutional appetite for West Coast commercial assets.
Ask follow-up questions
Fintool can predict
KRC's earnings beat/miss a week before the call